Literature DB >> 2369150

A CA125 score as a prognostic index in patients with ovarian cancer.

A Rosen1, P Sevelda, M Klein, J Spona, A Beck.   

Abstract

Due to its high specificity (90%) and sensitivity (86%) measurement of CA125 has become well-established in patients with epithelial ovarian cancer. We have formulated a CA125 prognostic score and examined its validity as an additional prognosis index. This score is composed of two CA125 values (one determined preoperatively and one 1 month after operation). CA125 serum levels of 0-64 IU/ml received 1 point, levels of 65-299 IU/ml were given 2 points, and those greater than 300 IU/ml were given 3 points. These points are added to produce the CA125 prognostic score. Statistical comparison demonstrated that patients with scores of 2 or 3 had a significantly (P = 0.0005) better prognosis than patients with scores of 4, 5 or 6. The classical prognostics features such as the FIGO stage, residual tumor mass and ascites were found to correlate with the CA125 prognostic score.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2369150     DOI： 10.1007/bf02390860

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN： 0932-0067            Impact factor:   2.344


  7 in total

1.  [Experiences with CA 125, a tumor marker for malignant epithelial ovarian tumors].

Authors:  G Crombach; H H Zippel; H Würz
Journal:  Geburtshilfe Frauenheilkd       Date:  1985-04       Impact factor: 2.915

2.  Survival of patients following secondary cytoreductive surgery in ovarian cancer.

Authors:  J S Berek; N F Hacker; L D Lagasse; R K Nieberg; R M Elashoff
Journal:  Obstet Gynecol       Date:  1983-02       Impact factor: 7.661

3.  Epithelial carcinoma of the ovary:prognostic importance of histologic grade.

Authors:  T G Day; H S Gallager; F N Rutledge
Journal:  Natl Cancer Inst Monogr       Date:  1975-10

4.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

5.  [Clinical significance of the tumor marker CA-125 for the preoperative diagnosis and postoperative management of patients with malignant ovarian cancers].

Authors:  P Sevelda; H Salzer; C Dittrich; J Spona
Journal:  Geburtshilfe Frauenheilkd       Date:  1985-11       Impact factor: 2.915

6.  Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas.

Authors:  T L Klug; R C Bast; J M Niloff; R C Knapp; V R Zurawski
Journal:  Cancer Res       Date:  1984-03       Impact factor: 12.701

7.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245
  7 in total
  7 in total

1.  Non-ovarian peritoneal papillary serous carcinoma with high CA125 levels.

Authors:  H R Rosen; A C Rosen; J Preiser; M Stierer; M Klein; H Hanak
Journal:  Arch Gynecol Obstet       Date:  1992       Impact factor: 2.344

2.  Use of tumour marker immunoreactivity to identify primary site of metastatic cancer.

Authors:  A R Gamble; J A Bell; J E Ronan; D Pearson; I O Ellis
Journal:  BMJ       Date:  1993-01-30

3.  Preoperative and postoperative CA-125 serum levels in primary fallopian tube carcinoma.

Authors:  A C Rosen; M Klein; H R Rosen; A H Graf; M Lahousen; A Reiner; N Vavra; L Auerbach
Journal:  Arch Gynecol Obstet       Date:  1994       Impact factor: 2.344

4.  First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.

Authors:  A Rosen; P Sevelda; M Klein; K Dobianer; C Hruza; K Czerwenka; H Hanak; N Vavra; H Salzer; S Leodolter
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

5.  The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.

Authors:  J Fisken; R C Leonard; M Stewart; G J Beattie; C Sturgeon; L Aspinall; J E Roulston
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

6.  Tumour-associated trypsin inhibitor (TATI): comparison with CA125 as a preoperative prognostic indicator in advanced ovarian cancer.

Authors:  P Venesmaa; P Lehtovirta; U H Stenman; A Leminen; M Forss; O Ylikorkala
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

7.  Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.

Authors:  Nienke Zwakman; Rafli van de Laar; Toon Van Gorp; Petra L M Zusterzeel; Marc P M L Snijders; Isabel Ferreira; Leon F A G Massuger; Roy F P M Kruitwagen
Journal:  J Gynecol Oncol       Date:  2016-09-12       Impact factor: 4.401
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.